Perone Thomas Michael 4
4 · Ovid Therapeutics Inc. · Filed Apr 29, 2021
Insider Transaction Report
Form 4
Perone Thomas Michael
SVP, General Counsel
Transactions
- Award
Stock Option (Right to Buy)
2020-11-25+44,000→ 44,000 totalExercise: $3.66From: 2020-11-25Exp: 2030-05-04→ Common Stock (44,000 underlying)
Footnotes (1)
- [F1]On May 5, 2020, the Reporting Person was granted the option to purchase shares of the Issuer's common stock, subject to a performance-based vesting condition to be satisfied upon the achievement of a particular milestone related to the Issuer's clinical trial, and further subject to the Reporting Person's continuous service through such vesting date. Such option vested in full on November 25, 2020 upon the satisfaction of such performance-based vesting condition.